ExoPTEN nasal spray - The holy biotech grail in the financial world? A new hope for Nurexone Biologic Inc. (WKN: A3DNSU) investors in sight!

ExoPTEN nasal spray - The holy biotech grail in the financial world? A new hope for Nurexone Biologic Inc. (WKN: A3DNSU) investors in sight!

According to a report from www.ariva.de,

Nurexone Biologic Inc.* (NASDAQ:NUR) stock has experienced a spectacular rally in the last four trading days, bringing gains of almost 300%. This increase is due to the possibility that the nasal spray “ExoPTEN” may be able to cure acute spinal cord injuries. CEO Dr. Lior Shatiel suggests that the exosome technology on which the nasal spray is based could also be used to cure other diseases where medication has so far failed to cross the blood-brain barrier.

The awarding of “orphan drug status” by the US Food and Drug Administration (FDA) is arousing great interest and analysts are expecting price gains of over 1,000% for this innovative product from Israel.

The use of exosomes as carriers for modified siRNA has already shown significant motor improvement, sensory recovery and rapid recovery of the urinary reflex in spinal cord injuries in animal studies. This has the potential to significantly reduce the cost of care and treatment for such injuries. The European Medicines Agency EMA is also showing interest in the technology.

Other major pharmaceutical companies such as Roche, Jazz Pharma, Takeda and Eli Lilly have already made significant investments in exosome technology, highlighting the immense potential of this innovative form of therapy.

The ability to cure acute spinal cord injuries with a nasal spray is a unique and potentially transformative development. The success of this technology could have a significant impact on the market, consumers and the entire industry. The share price of Nurexone Biologic Inc.* (WKN: A3DNSU) could rise significantly if the ExoPTEN nasal spray is successfully launched.